GSK plc (GSK) Goldman Sachs 9th Annual Biopharma Innovation Summit March 26, 2026 5:00 AM EDT
Company Participants
Kaivan Khavandi – Senior VP, Global Head of Respiratory, Immunology, Inflammation and Research & Development
Conference Call Participants
Rajan Sharma – Goldman Sachs Group, Inc., Research Division
Presentation
Rajan Sharma
Goldman Sachs Group, Inc., Research Division
Good morning, everyone, and thanks for joining on day 3 of our Biopharma Innovation Summit. Very pleased to start the day this morning with a fireside chat with Kaivan Khavandi, who’s Head of Respiratory, Inflammation and Immunology, R&D at GSK, quite a lot of disease areas there.
So Kaivan, thank you for joining us. Maybe just to kick off, if you could just give us a brief intro on yourself and your background, which just for people who may be less familiar.
Kaivan Khavandi
Senior VP, Global Head of Respiratory, Immunology, Inflammation and Research & Development
Sure. Yes. So I’m a physician scientist, trained in inflammatory mechanisms of cardiopulmonary risk, had a lab at King’s College London, and practice at Guy’s and St. Thomas’. I’ve worked in the industry across large pharma, Pfizer, GSK, across I&I, internal medicine, cardiovascular medicine and also a brief stint at BenevolentAI as CMO. And at GSK, I lead an organization that spans from target concepts through to approval for Specialty Medicines, as Rajan said, spanning respiratory, immunology and inflammation and also lead an organization across enterprise at GSK for translational sciences.
Question-and-Answer Session
Rajan Sharma
Goldman Sachs Group, Inc., Research Division
Perfect. So within those areas, there’s obviously a lot of catalysts this year. And maybe we’ll start with camlipixant. So we’ve got the Phase III readout coming later this year. Before we get into the details, can we just talk through the opportunity in chronic cough? I think it’s something that’s still debated amongst investors and
